A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
DIASORIN operates in the Medical - Diagnostics & Research industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 1.3B | 1.3B | 1.2B | 1.4B | 1.5B | 1.0B |
| Net Income | 203M | 203M | 174M | 253M | 367M | 285M |
| EPS | $3.62 | $3.62 | $3.12 | $4.37 | $6.37 | $5.17 |
| Free Cash Flow | 331M | 331M | 289M | 354M | 392M | 301M |
| ROIC | 13.7% | 8.2% | 6.9% | 10.6% | 22.1% | 38.1% |
| Gross Margin | 65.9% | 65.9% | 64.6% | 66.2% | 66.6% | 68.4% |
| Debt/Equity | 0.00 | 0.54 | 0.70 | 0.81 | 0.95 | 0.03 |
| Dividends/Share | $1.18 | $1.24 | $1.15 | $1.11 | $1.13 | $1.09 |
| Operating Income | 279M | 279M | 235M | 370M | 495M | 372M |
| Operating Margin | 21.8% | 21.8% | 18.8% | 25.8% | 33.9% | 36.8% |
| ROE | 10.4% | 11.2% | 10.6% | 15.7% | 27.1% | 26.0% |
| Shares Outstanding | 56M | 56M | 56M | 58M | 57M | 55M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.0B | 1.5B | 1.4B | 1.2B | 1.3B | 1.3B |
| Gross Margin | 68.4% | 66.6% | 66.2% | 64.6% | 65.9% | 65.9% |
| R&D | -58M | -83M | -102M | -99M | -99M | -99M |
| SG&A | 378M | 561M | 680M | 669M | 664M | 664M |
| EBIT | 372M | 495M | 370M | 235M | 279M | 279M |
| Op. Margin | 36.8% | 33.9% | 25.8% | 18.8% | 21.8% | 21.8% |
| Net Income | 285M | 367M | 253M | 174M | 203M | 203M |
| Net Margin | 28.2% | 25.1% | 17.6% | 13.9% | 15.9% | 15.9% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | 38.1% | 22.1% | 10.6% | 6.9% | 8.2% | 13.7% |
| ROE | 26.0% | 27.1% | 15.7% | 10.6% | 11.2% | 10.4% |
| ROA | 19.9% | 14.0% | 6.8% | 4.9% | 5.8% | 5.7% |
| Cash Flow | ||||||
| Op. Cash Flow | 350M | 473M | 410M | 338M | 388M | 388M |
| Free Cash Flow | 301M | 392M | 354M | 289M | 331M | 331M |
| Owner Earnings | 272M | 352M | 239M | 179M | 236M | 236M |
| CapEx | 49M | 81M | 56M | 49M | 56M | 56M |
| Maint. CapEx | 70M | 113M | 161M | 149M | 139M | 139M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 70M | 113M | 161M | 149M | 139M | 139M |
| CapEx/OCF | 13.9% | 17.1% | 13.7% | 14.6% | 14.5% | 14.5% |
| Capital Allocation | ||||||
| Dividends Paid | 60M | 65M | 60M | 64M | 66M | 66M |
| Dividend Yield | 0.6% | 0.6% | 0.8% | 1.1% | 1.1% | 1.9% |
| Share Buybacks | 30M | 10M | 168M | 20M | 0 | 0 |
| Buyback Yield | 0.3% | 0.1% | 2.1% | 0.4% | 0.0% | 0.0% |
| Stock-Based Comp | 7.9M | 7.6M | 10M | 11M | 12M | 12M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -355M | 1.1B | 1.0B | 871M | 673M | -372M |
| Cash & Equiv. | 390M | 476M | 255M | 304M | 372M | 372M |
| Long-Term Debt | 35M | 1.5B | 1.3B | 1.2B | 1.0B | 1.0B |
| Debt/Equity | 0.03 | 0.95 | 0.81 | 0.70 | 0.54 | 0.00 |
| Interest Coverage | N/A | 18.3 | 10.0 | 7.1 | 9.0 | 9.0 |
| Equity | 1.1B | 1.6B | 1.6B | 1.7B | 1.9B | 1.9B |
| Total Assets | 1.4B | 3.8B | 3.6B | 3.5B | 3.6B | 3.6B |
| Total Liabilities | 333M | 2.2B | 2.0B | 1.8B | 1.6B | 1.6B |
| Intangibles | N/A | 1.4B | N/A | 1.2B | 1.3B | 1.3B |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 636M | 779M | N/A | 719M | 748M | 748M |
| Current Assets | 820M | 1.1B | N/A | 1.1B | 1.0B | 1.0B |
| Current Liabilities | 184M | 352M | N/A | 348M | 297M | 297M |
| Per Share Data | ||||||
| EPS | 5.17 | 6.37 | 4.37 | 3.12 | 3.62 | 3.62 |
| Owner EPS | 4.96 | 6.16 | 4.13 | 3.21 | 4.21 | 4.21 |
| Book Value | 20.04 | 28.21 | 27.72 | 29.99 | 34.65 | 34.65 |
| Cash Flow/Share | 6.38 | 8.27 | 7.10 | 6.08 | 6.90 | 6.10 |
| Dividends/Share | 1.09 | 1.13 | 1.11 | 1.15 | 1.24 | 1.18 |
| Shares Out. | 54.8M | 57.2M | 57.7M | 55.7M | 56.2M | 56.2M |
| Valuation | ||||||
| P/E Ratio | 40.6 | 28.2 | 31.8 | 33.1 | 28.7 | 16.9 |
| P/FCF | 38.2 | 26.2 | 22.7 | 19.9 | 17.6 | 10.4 |
| EV/EBIT | 30.0 | 22.9 | 24.5 | 28.2 | 23.3 | 11.0 |
| Price/Book | 10.5 | 6.4 | 5.0 | 3.4 | 3.0 | 1.8 |
| Price/Sales | 11.4 | 7.0 | 5.6 | 4.6 | 4.6 | 2.7 |
| FCF Yield | 2.6% | 3.8% | 4.4% | 5.0% | 5.7% | 9.6% |
| Market Cap | 11.5B | 10.3B | 8.0B | 5.7B | 5.8B | 3.4B |
| Avg. Price | 177.57 | 197.03 | 137.39 | 108.69 | 105.06 | 61.26 |
| Year-End Price | 209.96 | 179.90 | 138.93 | 103.08 | 104.00 | 61.26 |
DIASORIN passes 4 of 9 quality checks, suggesting mixed fundamentals.
DIASORIN trades at 16.9x trailing earnings, compared to its 15-year median P/E of 31.8x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 10.4x vs a median of 22.7x. The company's 5-year average ROIC is 17.2% with a gross margin of 66.3%. Total shareholder yield (dividends) is 1.9%. At current prices, the estimated annualized return to fair value is +0.6%.
DIASORIN (DIA-MI) has a current P/E ratio of 16.9, compared to its historical median P/E of 31.8. The stock is currently considered Cheap based on its historical valuation range.
DIASORIN (DIA-MI) has a 5-year average return on invested capital (ROIC) of 17.2%. This indicates strong capital allocation and a potential competitive advantage.
DIASORIN (DIA-MI) has a market capitalization of $3.4B. It is classified as a mid-cap stock.
Yes, DIASORIN (DIA-MI) pays a dividend with a trailing twelve-month yield of 1.92%.
Based on historical P/E analysis, DIASORIN (DIA-MI) appears cheap. The current P/E of 16.9 is 47% below its historical median of 31.8. The estimated fair value CAGR (P/E method) is -7.4%.
DIASORIN (DIA-MI) operates in the Medical - Diagnostics & Research industry, within the Healthcare sector.
DIASORIN (DIA-MI) reported annual revenue of $1.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
DIASORIN (DIA-MI) has a net profit margin of 15.9%. This is a healthy margin.
DIASORIN (DIA-MI) generated $331 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
DIASORIN (DIA-MI) has a debt-to-equity ratio of 0.54. This indicates moderate leverage.
DIASORIN (DIA-MI) reported earnings per share (EPS) of $3.62 in its most recent fiscal year.
DIASORIN (DIA-MI) has a return on equity (ROE) of 11.2%. This indicates moderate shareholder returns.
DIASORIN (DIA-MI) has a 5-year average gross margin of 66.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for DIASORIN (DIA-MI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
DIASORIN (DIA-MI) has a book value per share of $34.65, based on its most recent annual SEC filing.